Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MCRPC (metastatic Castration-resistant Prostate Cancer)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06972628
What this trial is testing

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

Who this might be right for
Metastatic Castration-Resistant Prostate CancerProstate Cancer Patients With Bone MetastasisProstate Cancer (CRPC)+2 more
Ebrahim S Delpassand 30
Large-scale testing (Phase 3)Study completedNCT03016312
What this trial is testing

Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Hoffmann-La Roche 759
Testing effectiveness (Phase 2)Ended earlyNCT03712930
What this trial is testing

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)Homologous Recombination Deficiency (HRD)
BeiGene 13
Large-scale testing (Phase 3)Active Not RecruitingNCT05348577
What this trial is testing

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
AstraZeneca 1,035
Early research (Phase 1)Active Not RecruitingNCT06305598
What this trial is testing

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Roswell Park Cancer Institute 3
Early research (Phase 1)Looking for participantsNCT07621692
What this trial is testing

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
National Taiwan University Hospital 12
Testing effectiveness (Phase 2)Looking for participantsNCT06126731
What this trial is testing

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Institute of Cancer Research, United Kingdom 39
Testing effectiveness (Phase 2)Looking for participantsNCT06609005
What this trial is testing

Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Advanced Metastatic Castration Resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd. 84
Testing effectiveness (Phase 2)Active Not RecruitingNCT06334432
What this trial is testing

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorHER2-negative Breast CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)+2 more
Nuvation Bio Inc. 466
Testing effectiveness (Phase 2)Study completedNCT05670106
What this trial is testing

Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 62
Very early researchNot Yet RecruitingNCT07389187
What this trial is testing

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
mCRPC
Shanghai Changzheng Hospital 10
Not applicableStudy completedNCT02230059
What this trial is testing

Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 382
Testing effectiveness (Phase 2)Study completedNCT01487863
What this trial is testing

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer MetastaticHormone Refractory Prostate CancerCastration-resistant Prostate Cancer
Dendreon 69
Not applicableStudy completedNCT03223727
What this trial is testing

Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223

Who this might be right for
Prostate Cancer MetastaticBone Metastases
The Netherlands Cancer Institute 100
Not applicableWithdrawnNCT03325127
What this trial is testing

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Bayer
Testing effectiveness (Phase 2)Study completedNCT03480646
What this trial is testing

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Constellation Pharmaceuticals 175
Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Very early researchNot Yet RecruitingNCT07381582
What this trial is testing

Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
Peking Union Medical College Hospital 15
Large-scale testing (Phase 3)Looking for participantsNCT06520345
What this trial is testing

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited 520
Testing effectiveness (Phase 2)UnknownNCT03700099
What this trial is testing

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Instituto do Cancer do Estado de São Paulo 30
Next Page